I’rom Group dividend yield – I’ROM GROUP Declares 20.0 Cash Dividend
March 22, 2023
Dividends Yield
On March 1 2023, I’ROM GROUP ($TSE:2372) declared a 20.0 cash dividend. Over the past three years, the company has been paying an annual dividend per share of 40.0 JPY. Analysts predict that the dividend yields from 2021 to 2023 will be 2.23%, 1.74%, and 2.26% respectively, with an average dividend yield of 2.08%. For investors looking to invest in dividend stocks, I’ROM GROUP is an attractive option, with the ex-dividend date being March 30 2023.
With this dividend payout, I’ROM GROUP has demonstrated its commitment to rewarding shareholders with a consistent dividend income. Investment in I’ROM GROUP stocks is likely to bring good returns for investors looking for steady and sustainable income from their investments.
Market Price
The stock opened at JP¥1948.0 and closed at JP¥1888.0, representing a 3.1% decrease from the previous closing price of JP¥1948.0. This announcement has caused a slight decrease in the share price, with investors taking a wait-and-see approach to the dividend announcement. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for I’rom Group. More…
| Total Revenues | Net Income | Net Margin |
| 17.91k | 2.42k | 15.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for I’rom Group. More…
| Operations | Investing | Financing |
| 4.51k | -2.92k | 2.68k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for I’rom Group. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 32.22k | 20.39k | 977.03 |
Key Ratios Snapshot
Some of the financial key ratios for I’rom Group are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 21.8% | 57.1% | 18.6% |
| FCF Margin | ROE | ROA |
| 6.3% | 17.5% | 6.5% |
Analysis
GoodWhale has conducted an analysis of I’ROM GROUP‘s financials, and based on our Risk Rating report, I’ROM GROUP is considered to be a high risk investment. During our process of analyzing the company’s income sheet, balance sheet, and cashflow statement, we have identified 3 risk warnings that should be taken into account when considering investing in I’ROM GROUP. Our detailed risk report is available to registered users; sign up today to gain access to this valuable insight. More…
Peers
I”rom Group Co Ltd is one of the leading pharmaceutical companies in the world, alongside its competitors Medinex Ltd, M1 Kliniken AG, and Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co Ltd. These companies are dedicated to providing innovative medicines and treatments to customers around the world. They strive to make healthcare available and accessible to everyone.
– Medinex Ltd ($SGX:OTX)
Medinex Ltd is a provider of medical products and services to customers around the world. The company has a market capitalization of 25.87 million dollars as of 2023, indicating the total value of its outstanding shares. Additionally, Medinex Ltd has a Return on Equity (ROE) of 7.12%, which measures the profitability of a company in relation to the amount of equity or shareholders’ funds it has. This relatively high ROE indicates that Medinex Ltd is able to generate significant profits from its existing resources, making it attractive to potential investors.
– M1 Kliniken AG ($OTCPK:MKLNF)
M1 Kliniken AG is a German-based company that provides health care services. It has a market capitalization of 129.35 million euros as of 2023. This market cap represents the sum of equity shares that the company has issued, and is used to measure the size of the company relative to its peers. M1 Kliniken AG also enjoys a relatively strong return on equity (ROE) of 7.32%, which reflects the efficiency of the organization in generating returns from its investments. This strong ROE indicates that the company has good financial control and is able to generate good returns on its investments in the form of profits.
– Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co Ltd ($SZSE:300937)
Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd is a Chinese pharmaceutical company with a market cap of 2.82 billion as of 2023. It is focused on providing prescription and nonprescription drugs, as well as other related products and services. The company has shown strong growth over the years, with a return on equity of 0.68%. This indicates that it is efficiently leveraging its shareholders’ capital in order to generate higher returns. The company also has a strong presence in the Chinese pharmaceutical market, being one of the leading players. It has a wide range of products including antibiotics, anti-infectives and analgesics.
Summary
I’ROM GROUP is a reliable investment option for investors interested in dividend stocks. In the past 3 years, the company has paid a consistent annual dividend per share of 40 JPY. For the next 3 years, 2021-2023, the dividend yield is estimated to be around 2.23%, 1.74% and 2.26% respectively, giving an average yield of 2.08%. The consistency of dividends combined with the overall attractive yield makes I’ROM GROUP a good option for investors seeking a steady income stream with potential growth.
